CCNB2 expression correlates with worse outcomes in breast cancer patients: a pooled analysis

References

• Barrett, T., S. E. Wilhite, and P. Ledoux, C. Evangelista, I. F. Kim, M. Tomashevsky, K. A. Marshall, K. H. Phillippy, P. M. Sherman, M. Holko et al. 2013. NCBI GEO: Archive for functional genomics data sets—update. Nucleic Acids Research 41(Database issue):D991–5. doi:10.1093/nar/gks1193.
   PubMed Web of Science ®Google Scholar
• Barrett, T., S.E. Wilhite, P. Ledoux. et al., 2013. NCBI GEO: Archive for functional genomics data sets--update. Nucleic Acids Research. 41(Database issue):D991–D995. doi:10.1093/nar/gks1193.
   PubMed Web of Science ®Google Scholar
• Begg, C. B., and M. Mazumdar. 1994. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (4):1088–101. doi:10.2307/2533446.
   PubMed Web of Science ®Google Scholar
• Bostanabad, S. Y., S. Noyan, B. G. Dedeoglu, and H. Gurdal. 2021. Overexpression of β-Arrestins inhibits proliferation and motility in triple negative breast cancer cells. Scientific Reports 11 (1):1539. doi:10.1038/s41598-021-80974-6.
   PubMed Web of Science ®Google Scholar
• Cao, J., S. Sun, R. Min, and R. Li, X. Fan, Y. Han, Z. Feng, N. Li, et al. 2021. Prognostic significance of CCNB2 expression in triple-negative breast cancer. Cancer Management Andresearch 13:9477–87. doi:10.2147/CMAR.S339105
   Web of Science ®Google Scholar
• DerSimonian, R., and N. Laird. 1986. Meta-Analysis in clinical trials. Controlled Clinical Trials 7 (3):177–88. doi:10.1016/0197-2456(86)90046-2.
   PubMedGoogle Scholar
• Draetta, G., F. Luca, J. Westendorf, L. Brizuela, J. Ruderman, and D. Beach. 1989. Cdc2 protein kinase is complexed with both cyclin a and B: Evidence for proteolytic inactivation of MPF. Cell 56 (5):829–38. doi:10.1016/0092-8674(89)90687-9.
   PubMed Web of Science ®Google Scholar
• Egger, M., G. Davey Smith, M. Schneider, and C. Minder. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed) 315 (7109):629–34. doi:10.1136/bmj.315.7109.629.
   PubMed Web of Science ®Google Scholar
• Giunchi, F., T. Franceschini, and M. Fiorentino. 2021. A narrative review of individualized treatments of genitourinary tumors: Is the future brighter with molecular evaluations? Translational Andrology and Urology 10 (3):1553–61. doi:10.21037/tau-20-1185.
   PubMed Web of Science ®Google Scholar
• Gui, L., and H. Homer. 2013. Hec1-Dependent cyclin B2 stabilization regulates the G2-M transition and early prometaphase in mouse oocytes. Developmental Cell 25 (1):43–54. doi:10.1016/j.devcel.2013.02.008.
   PubMed Web of Science ®Google Scholar
• Győrffy, B. 2021. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Computational and Structural Biotechnology Journal 19:4101–09. doi:10.1016/j.csbj.2021.07.014.
   PubMed Web of Science ®Google Scholar
• Haidich, A. B. 2010. Meta-Analysis in medical research. Hippokratia 14 (Suppl 1):29–37.
   PubMed Web of Science ®Google Scholar
• Hamann, M., S. Grill, J. Struck, A. Bergmann, O. Hartmann, M. Pölcher, M. Kiechle et al. 2019. Detection of early breast cancer beyond mammographic screening: A promising biomarker panel. Biomarkers in Medicine 13(13):1107–17. doi:10.2217/bmm-2019-0085.
   PubMed Web of Science ®Google Scholar
• Higgins, J. P., and S. G. Thompson. 2002. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 21 (11):1539–58. doi:10.1002/sim.1186.
   PubMed Web of Science ®Google Scholar
• Jayanthi, V., A. B. Das, and U. Saxena. 2020. Grade-Specific diagnostic and prognostic biomarkers in breast cancer. Genomics 112 (1):388–96. doi:10.1016/j.ygeno.2019.03.001.
   PubMed Web of Science ®Google Scholar
• Lei, C. Y., W. Wang, Y. T. Zhu, W. Y. Fang, and W. L. Tan. 2016. The decrease of cyclin B2 expression inhibits invasion and metastasis of bladder cancer. Urologic Oncology: Seminars and Original Investigations 34 (5): 237.e1-10. doi:10.1016/j.urolonc.2015.11.011.
   PubMed Web of Science ®Google Scholar
• Li, H., X. Sun, and E. Miller, Q. Wang, P. Tao, L. Liu, Y. Zhao, M. Wang, Y. Qi, J. Li et al. 2017. BMI, reproductive factors, and breast cancer molecular subtypes: A case-control study and meta-analysis. Journal of Epidemiology 27(4):143–51. doi:10.1016/j.je.2016.05.002.
   PubMed Web of Science ®Google Scholar
• Li, J., Y. C. Ouyang, C. H. Zhang, W. P. Qian, and Q. Y. Sun. 2019. The cyclin B2/CDK1 complex inhibits separase activity in mouse oocyte meiosis I. Development (Cambridge, England) 146 (23):dev182519. doi:10.1242/dev.182519.
   PubMed Web of Science ®Google Scholar
• Liu, L., A. Chen, S. Chen, et al. 2020. CCNB2, NUSAP1 and TK1 are associated with the prognosis and progression of hepatocellular carcinoma, as revealed by co-expression analysis. Experimental and Therapeutic Medicine 19 (4):2679–89. doi:10.3892/etm.2020.8522.
   PubMed Web of Science ®Google Scholar
• Mattiuzzi, C., and G. Lippi. 2019. Current cancer epidemiology. Journal of Epidemiology and Global Health 9 (4):217–22. doi:10.2991/jegh.k.191008.001.
   PubMed Web of Science ®Google Scholar
• Meng, C., Y. Zou, W. Hong, C. Bao, and X. Jia. 2020. Estrogen-Regulated PTTG1 promotes breast cancer progression by regulating cyclin kinase expression. Molecular Medicine (Cambridge, Mass) 26 (1):33. doi:10.1186/s10020-020-00161-7.
   PubMed Web of Science ®Google Scholar
• Mizuno, H., K. Kitada, K. Nakai, and A. Sarai. 2009. PrognoScan: A new database for meta-analysis of the prognostic value of genes. BMC Medical Genomics 2:18. doi:10.1186/1755-8794-2-18.
   PubMed Web of Science ®Google Scholar
• Moradpoor, R., H. Zali, A. Gharebaghian, M. E. Akbari, S. Ajdari, and M. Salimi. 2021. Identification of CCNB2 as a potential non-invasive breast cancer biomarker in peripheral blood mononuclear cells using the systems biology approach. Cell Journal 23 (4):406–13. doi:10.22074/cellj.2021.7053.
   PubMed Web of Science ®Google Scholar
• Najafi, S., M. Sadeghi, F. Abasvandi, M. R. Shajari, K. Mohebi, and H. Ghandchi. 2019. Prognostic factors influencing prognosis in early breast cancer patients. Przeglad Menopauzalny 18 (2):82–88. doi:10.5114/pm.2019.86833.
   PubMedGoogle Scholar
• Petri, E. T., A. Errico, L. Escobedo, T. Hunt, and R. Basavappa. 2007. The crystal structure of human cyclin B. Cell Cycle (Georgetown, Tex) 6 (11):1342–49. doi:10.4161/cc.6.11.4297.
   PubMed Web of Science ®Google Scholar
• Qian, X., X. Song, Y. He, Z. Yang, T. Sun, J. Wang, G. Zhu, W. Xing, and C. You. 2015. CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients. Biomed Pharmacother 74:222–27. doi:10.1016/j.biopha.2015.08.004.
   PubMed Web of Science ®Google Scholar
• Qiu, P., Q. Guo, Q. Yao, J. Chen, J. Lin, and S. Chang. 2021. Hsa-Mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer. PloS One 16 (11):e0254283. doi:10.1371/journal.pone.0254283.
   PubMed Web of Science ®Google Scholar
• Shirdarreh, M., O. Aziza, R. C. Pezo, K. J. Jerzak, and E. Warner. 2021. Patients’ and oncologists’ knowledge and expectations regarding tumor multigene next-generation sequencing: A narrative review. The Oncologist 26 (8):e1359–71. doi:10.1002/onco.13783.
   PubMed Web of Science ®Google Scholar
• Shubbar, E., A. Kovács, S. Hajizadeh, et al. 2013. Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer 13:1. doi:10.1186/1471-2407-13-1.
   PubMed Web of Science ®Google Scholar
• Sung, H., J. Ferlay, R.L. Siegel. et al., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 71(3):209–49. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Wu, T., X. Zhang, X. Huang, Y. Yang, and X. Hua. 2010. Regulation of cyclin B2 expression and cell cycle G2/m transition by menin. TThe Journal of Biological Chemistry 285 (24):18291–300. doi:10.1074/jbc.M110.106575.
   PubMed Web of Science ®Google Scholar
• Wu, S., R. Su, H. Jia, and A. Birková. 2021. Cyclin B2 (CCNB2) stimulates the proliferation of Triple-Negative Breast Cancer (TNBC) cells in vitro and in vivo. Disease Markers 2021:5511041. doi:10.1155/2021/5511041.
   PubMed Web of Science ®Google Scholar
• Yang, K., J. Gao, and M. Luo. 2019. Identification of key pathways and hub genes in basal-like breast cancer using bioinformatics analysis. OncoTargets and Therapy 12:1319–31. doi:10.2147/OTT.S158619.
   PubMed Web of Science ®Google Scholar